TNFRSF18 and melanoma: Preliminary results of a humanized monoclonal antibody (TRX518) that triggers GITR, given as monotherapy to patients with refractory solid tumors (including melanoma), demonstrated that TRX518 reduces circulating and intratumoral Treg cells to a similar extent, providing an easily evaluable biomarker of anti-GITR activity [55].